Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

RPT193

Small molecule · Antagonist of C-C chemokine receptor type 4 (CCR4) · developed by RAPT Therapeutics, Inc., a member of the GSK plc group of companies

Phase 2 Most advanced trial (none active)
GSK Developer
2 Registered trials

What is RPT193?

RPT193 is an antagonist of the chemokine receptor CCR4. It inhibits CCR4-mediated chemotaxis toward the ligands CCL22 and CCL17. It is being studied in asthma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
C-C chemokine receptor type 4 (CCR4)
Mechanism
Antagonist of C-C chemokine receptor type 4 (CCR4)
Pathways
CCR4-mediated chemotaxis, CCL22 and CCL17 signaling
Therapy area
Respiratory
Developer
RAPT Therapeutics, Inc., a member of the GSK plc group of companies (GSK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05935332 Phase 2 Asthma Terminated GSK
NCT06087978 Phase 1 Healthy Male Subjects Completed GSK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AsthmaHealthy Male Subjects

Other drugs acting on CCR4

More from RAPT Therapeutics, Inc., a member of the GSK plc group of companies

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the GSK page.

Follow GSK, the company behind RPT193

See GSK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GSK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.